Press release
HSV-1 Keratitis Competitive Landscape, 2025: Breaking Barriers in Herpetic Eye Disease Treatment
HSV-1 Keratitis Competitive Landscape
While current standards like acyclovir and ganciclovir remain foundational, pipeline products are exploring immune modulators, sustained-release antivirals, and gene therapies that address resistance, corneal scarring, and long-term suppression. Players such as NanoViricides, Okogen, and Trefoil Therapeutics are developing targeted options with novel mechanisms of action and extended dosing intervals.
The report also reviews inactive and discontinued assets, helping stakeholders track shifting priorities and identify white spaces in the HSV-1 keratitis market. Detailed segmentation by stage, molecule type, and delivery route offers strategic insights into areas of intense competition and untapped opportunity.
With HSV-1 keratitis contributing significantly to infectious blindness worldwide, and recurrent infections posing major therapeutic challenges, this landscape is on the verge of disruption. DelveInsight's competitive analysis offers essential intelligence for investors, developers, and decision-makers navigating this evolving market.
Interested in learning more about the current treatment landscape and the key drivers shaping the HSV-1 keratitis pipeline? Click here: https://www.delveinsight.com/report-store/hsv-1-keratitis-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Key Takeaways from the HSV-1 Keratitis Competitive Landscape Report
• DelveInsight's HSV-1 keratitis competitive analysis depicts a strong space with 45+ active players working to develop 50+ drugs for HSV-1 keratitis treatment.
• The leading HSV-1 keratitis companies include AiCuris Anti-infective Cures AG, Shanghai BDgene Co., Ltd, Excision BioTherapeutics, Inc., and others are evaluating their lead assets to improve the HSV-1 keratitis treatment landscape.
• Key HSV-1 keratitis pipeline therapies in various stages of development include BD-111, EBT‐104, and others.
• In August 2024, Excision BioTherapeutics, Inc. announced the Molecular Therapy Methods & Clinical Development publication of a preclinical study of EBT-104 in herpes simplex virus-1 keratitis (HSV-1 Keratitis).
• In May 2024, a recent study published in the Virology Journal, a group of researchers evaluated the antiviral efficacy and therapeutic potential of harmol in treating herpes simplex virus type 1 (HSV-1) induced keratitis, including drug-resistant strains, and its ability to enhance the effects of acyclovir (ACV).
• In May 2024, AiCuris published pharmacokinetic data for its lead candidate pritelivir (AIC316), an innovative therapeutic candidate targeting HSV replication. Pritelivir is currently being evaluated in a Phase III trial for the treatment of acyclovir-resistant HSV infections in immunocompromised patients.
Request a sample and discover the recent breakthroughs happening in the HSV-1 keratitis competitive landscape at https://www.delveinsight.com/report-store/hsv-1-keratitis-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
HSV-1 Keratitis Overview
HSV-1 keratitis is a viral infection of the cornea caused by herpes simplex virus type 1, and is the leading cause of corneal blindness in developed nations. Though typically linked to oral infections, HSV-1 can spread to the eye through direct contact or reactivation from latency in the trigeminal ganglion, especially during illness, stress, or immunosuppression.
Common symptoms include eye pain, redness, blurred vision, tearing, and light sensitivity. Recurrent episodes can lead to corneal scarring and vision loss. The condition may begin as epithelial keratitis with dendritic ulcers and can progress to deeper stromal involvement, causing more severe complications. Diagnosis is mainly clinical using slit-lamp examination and fluorescein staining, with PCR tests used in unclear cases.
Treatment includes topical antivirals like trifluridine or ganciclovir, and oral agents such as acyclovir. Inflammatory forms may require corticosteroids, and long-term antivirals may be used to prevent recurrences.
Find out more about HSV-1 keratitis medication at https://www.delveinsight.com/report-store/hsv-1-keratitis-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
HSV-1 Keratitis: Company and Product Profiles (Marketed Therapies)
Company Overview: Novartis
Novartis International AG, headquartered in Switzerland, is a leading global pharmaceutical company founded in 1996 from the merger of Ciba-Geigy and Sandoz. It focuses on researching, developing, manufacturing, and marketing pharmaceuticals, generics, and biosimilars. Novartis is committed to sustainable healthcare, reducing environmental impact, and improving access to affordable medicines worldwide.
Product Description: Famciclovir
Famciclovir is an oral antiviral prodrug that converts to penciclovir in the body, inhibiting viral DNA replication to treat herpes virus infections, including HSV-1 and HSV-2. It is being studied for efficacy against HSV keratitis and is known for its long intracellular half-life, allowing sustained antiviral effects. Famvir® is a registered trademark of Novartis International Pharmaceutical Ltd.
HSV-1 Keratitis: Company and Product Profiles (Pipeline Therapies)
Company Overview: Shanghai BDgene Co., Ltd
Shanghai BDgene Co., Ltd., based in Shanghai, China, is a biotechnology firm specializing in genetic and genomic technologies. The company provides genetic testing services, including disease screening, drug metabolism analysis, and personalized medicine solutions. BDgene offers high-throughput sequencing and bioinformatics tools to support tailored medical treatments based on individual genetic profiles.
Product Description: Difelikefalin BD-111
BD-111 is a gene-editing therapy for viral keratitis, developed using BDgene's patented mRNA delivery technology. It has completed three human IIT clinical trials and is the world's only Cas9 mRNA delivery via lentivirus, as well as the second CRISPR-Cas9 gene-editing treatment tested in humans. BD-111 uses BDgene's VLP delivery system to transduce CRISPR, directly targeting and cleaving the HSV-1 viral genome to treat herpesvirus keratitis. The therapy delivers Cas9 mRNA with a short duration in the body, minimizing immune response and off-target effects. BD-111 edits only the viral genome without altering human DNA and is currently in Phase II development for HSV-1 keratitis.
Discover how emerging HSV-1 keratitis therapies stack up against current treatments in the evolving market landscape: https://www.delveinsight.com/report-store/hsv-1-keratitis-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
HSV-1 Keratitis Therapeutics Assessment
Company Analysis
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs
Scope of the HSV-1 Keratitis Competitive Landscape Report
• Coverage: Global
• Key HSV-1 Keratitis Companies: AiCuris Anti-infective Cures AG, Shanghai BDgene Co., Ltd, Excision BioTherapeutics, Inc., and others.
• Key HSV-1 Keratitis Pipeline Therapies: BD-111, EBT‐104, and others.
To dive deep into rich insights for drugs used for HSV-1 keratitis treatment, visit: https://www.delveinsight.com/report-store/hsv-1-keratitis-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. HSV-1 Keratitis Overview
4. Analytical & Commercial Assessment
5. Competitive Landscape
6. Marketed Therapies
7. Pipeline Therapies (by development stage)
8. Unmet Needs
9. Market Drivers & Barriers
10. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HSV-1 Keratitis Competitive Landscape, 2025: Breaking Barriers in Herpetic Eye Disease Treatment here
News-ID: 4101447 • Views: …
More Releases from DelveInsight
Insulin Resistance Pipeline Insight 2025: Pipeline Drugs, Metabolic Pathway Modu …
DelveInsight's "Insulin Resistance - Pipeline Insight, 2025" explores over 10+ therapies in development for insulin resistance, a metabolic condition strongly linked to type 2 diabetes, obesity, and cardiovascular disease. Despite lifestyle modification and insulin-sensitizing drugs like metformin being mainstays of management, many patients continue to face poor glycemic control and associated complications, underscoring the need for more effective insulin resistance treatments.
The insulin resistance pipeline is broadening with next-generation therapies targeting…
Uveal Melanoma Pipeline Insight 2025: 30+ Pipeline Drugs, Targeted Therapies, an …
DelveInsight's "Uveal Melanoma - Pipeline Insight, 2025" explores over 30+ therapies in development for uveal melanoma, a rare and aggressive intraocular malignancy with high metastatic potential, most commonly to the liver. Despite surgery and radiotherapy being standards for localized disease, patients with metastatic uveal melanoma face limited systemic treatment options, creating significant unmet needs in the uveal melanoma treatment landscape.
The uveal melanoma pipeline is diversifying with next-generation targeted therapies, including…
Peptic Ulcers Pipeline Insight 2025: Emerging Therapies and Clinical Trials Shap …
DelveInsight's "Peptic Ulcers - Pipeline Insight, 2025" examines over 8+ therapies in development for peptic ulcer disease, a condition affecting millions worldwide with peptic ulcer disease symptoms such as abdominal pain, bloating, nausea, and gastrointestinal bleeding. Despite widespread use of existing peptic ulcer disease treatments, including proton pump inhibitors, H2 blockers, and antibiotics for H. pylori eradication, patients with recurrent or complicated peptic ulcers continue to face significant unmet needs,…
Vaso-Occlusive Crisis in Sickle Cell Disease: Emerging Therapies, Clinical Trial …
DelveInsight's "Vaso-Occlusive Crisis (VOC) Associated With Sickle Cell Disease - Pipeline Insight, 2025" provides an in-depth analysis of emerging therapies targeting vaso-occlusive crisis (VOC), a severe and recurring complication of sickle cell disease. Despite current standards of care, including hydroxyurea, patients continue to experience frequent vaso occlusive sickle cell crisis, underscoring the urgent need for effective interventions in sickle cell anemia vaso occlusive crisis treatment.
The VOC pipeline is diversifying with…
More Releases for HSV
Meeting HSV Singles in Arkansas: Love Knows No Boundaries
Nestled in the heart of the Natural State, an extraordinary community is emerging, one that defies stereotypes and embraces the true essence of connection - HSV singles in Arkansas are navigating the path to love with resilience and openness.
Renowned for its scenic beauty and warm hospitality, Arkansas has become a haven for a community that thrives on breaking down barriers. HSV singles in the state are not merely navigating…
Michigan Love Quest: Discovering the Perfect HSV Meeting Places
If you're living with HSV (Herpes Simplex Virus) and searching for love in Michigan, you've come to the right place. This comprehensive guide will delve into the best meeting spots specifically catered to HSV singles in the beautiful state of Michigan. Whether you're in bustling cities like Detroit or Ann Arbor or prefer the serene landscapes of Traverse City or Mackinac Island, we've got you covered. Let's embark on this…
Best Places to Meet HSV Singles in Colorado Springs
Welcome to our comprehensive guide on the best places to meet HSV singles in Colorado Springs. Suppose you're living with herpes and looking for meaningful connections. In that case, this guide is here to help you navigate the dating scene and discover supportive environments where you can meet like-minded individuals. We understand that meeting new people and forming romantic relationships can be challenging, but you can find love, support, and…
Texas's Best Meeting Places for HSV Singles
Welcome to our comprehensive guide on the best meeting places for HSV singles in Texas. In this article, we aim to assist individuals with HSV (Herpes Simplex Virus) in Texas by providing a valuable resource highlighting supportive and understanding communities where they can meet like-minded individuals. We understand the unique challenges HSV singles face in the dating world and recognize the importance of creating an inclusive environment where they can…
How to meet and Date Gay HSV Singles?
In movies, finding the right date seems so easy. But that's far away from the truth. After all, there are so many things that you need to do for finding the right person. Sometimes you might be even feeling frustrated for not finding any right gay HSV singles no matter how hard you tried.
But don't worry, finding the right partner is not that hard. All you need to do is…
Why should HSV singles take the decision of dating by own?
What does it mean when a partner tells others that he or she has herpes? On the open front, a number of thoughts will come in mind with reference to this question. It might be because he or she doesn’t want to cheat you or so. Surprisingly, you might not be ready with the apt answer. So this time, we are here to help you with the answer and enlighten…
